Umoja Biopharma Unveils Industry's First Dual-Targeted BCMA x GPRC5D In Vivo CAR T Therapy for Multiple Myeloma
核心洞察
Umoja Biopharma (搜索) announced UB-VV500, the industry's first combination BCMA (搜索) x GPRC5D (搜索) in vivo CAR T cell therapy designed to address antigen escape and disease heterogeneity in multiple myeloma (搜索).
The company plans to advance UB-VV500 into Phase 1 clinical trials by the end of 2026, building on encouraging safety and early clinical results from three ongoing Phase 1 programs.
Preclinical data for UB-VV500 will be presented at the American Society of Gene & Cell Therapy Annual Meeting, representing a shift toward dual-targeting strategies in multiple myeloma (搜索) treatment.
Umoja Biopharma (搜索) announced the acceptance of a poster presentation for UB-VV500, its dual-targeted BCMA (搜索) x GPRC5D (搜索) in vivo CAR T cell program for multiple myeloma (搜索) treatment, at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The therapy represents the industry's first combination approach targeting both BCMA and GPRC5D antigens through an in vivo CAR T cell platform.
Addressing Antigen Escape in Multiple Myeloma
"Development in multiple myeloma (搜索) is moving beyond single-targeted approaches toward dual-targeting and combination strategies, particularly as patients progress through existing BCMA (搜索)-directed therapies," said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma (搜索). The dual-targeting approach is designed to address antigen escape and disease heterogeneity, two significant challenges in current multiple myeloma treatment.
Dr. Scharenberg emphasized that "the future of multiple myeloma (搜索) immunotherapy will be shaped by combination products that are designed from the ground-up to more effectively address antigen escape and disease heterogeneity while aiming to deliver greater and more durable efficacy."
Clinical Development Timeline
Umoja expects to advance UB-VV500 into a Phase 1 clinical trial by the end of 2026. The company also plans to report initial clinical data disclosures across its other clinical programs at major medical meetings in the second half of 2026.
The development of UB-VV500 builds upon the company's VivoVec™ in vivo platform, which is currently being tested in three ongoing Phase 1 programs: UB-VV111 for CD19 (搜索) targeting and UB-VV400/UB-VV410 for CD22 (搜索) targeting. Dr. Scharenberg noted that the company is "encouraged by our safety and early clinical results" from these programs.
Scientific Presentation Details
The preclinical data for UB-VV500 will be presented in a scientific poster titled "Preclinical development of UB-VV500, an in vivo potency-enhanced CAR T cell product targeting BCMA (搜索) and GPRC5D (搜索) for multiple myeloma (搜索)" on Wednesday, May 13, 2026, from 5:00-6:30 p.m. ET. Christopher Nicolai, Ph.D., will serve as the presenting speaker for publication number 2046.
Technology Platform
UB-VV500 utilizes Umoja's VivoVec™ in vivo gene delivery technology, which empowers a patient's own immune system to fight disease. The company operates a state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado, supporting its core technology platform.
"Dual-targeting is the future of patient care for multiple myeloma (搜索), and we expect UB-VV500 to be at the forefront of that movement," Dr. Scharenberg concluded, highlighting the company's commitment to advancing combination immunotherapy approaches for multiple myeloma patients.